Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Lymphoma × orelabrutinib × Clear all

Phase

Status

Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1

Interventions

obinutuzumab 2 Rituximab 2 Immunotherapy, Adoptive 2 Bendamustine Hydrochloride 2 zanubrutinib 1 selinexor 1 sargramostim 1 orelabrutinib 1 glofitamab 1 Sulfasalazine 1 Sirolimus 1 Prednisone 1 Lenalidomide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡